The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S.

The Atlas-backed company plans to liquidate its assets, including an experimental drug for chronic spontaneous urticaria it ...

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of US ...

Wall Street analysts said the results for Verve’s therapy appeared competitive on efficacy, while avoiding any major safety ...

Signs of potential liver damage in a study participant led the company to abandon danuglipron, a drug it hoped would help it ...

Using integrated lab, claims, and EMR data, the manufacturer can pull in test results and deploy NLP on the unstructured EMR ...